カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界のガレクチン阻害治療薬市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Galectin Inhibitor Therapeutics Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19342）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19342
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：106
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界のガレクチン阻害治療薬市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

ガレクチン阻害治療薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のガレクチン阻害治療薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

ガレクチン阻害治療薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・天然、合成

用途別セグメントは次のように区分されます。
・糖尿病、心不全、喘息、関節リウマチ、その他

世界のガレクチン阻害治療薬市場の主要な市場プレーヤーは以下のとおりです。
・GlycoMimetics (US)、Galectin Therapeutics Inc (US)、G3 Pharmaceuticals (India)、iTeos (US)、MandalMed, Inc (US)、Angion (US)、Novartis AG (Switzerland)、Galecto Biotech (Denmark)、Pfizer Inc. (US)、Lilly (US)

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、ガレクチン阻害治療薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なガレクチン阻害治療薬メーカーの企業概要、2019年～2022年までのガレクチン阻害治療薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なガレクチン阻害治療薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別ガレクチン阻害治療薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのガレクチン阻害治療薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのガレクチン阻害治療薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびガレクチン阻害治療薬の産業チェーンを掲載しています。
・第13、14、15章では、ガレクチン阻害治療薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- ガレクチン阻害治療薬の概要
- 種類別分析（2017年vs2021年vs2028年）：天然、合成
- 用途別分析（2017年vs2021年vs2028年）：糖尿病、心不全、喘息、関節リウマチ、その他
- 世界のガレクチン阻害治療薬市場規模・予測
- 世界のガレクチン阻害治療薬生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- GlycoMimetics (US)、Galectin Therapeutics Inc (US)、G3 Pharmaceuticals (India)、iTeos (US)、MandalMed, Inc (US)、Angion (US)、Novartis AG (Switzerland)、Galecto Biotech (Denmark)、Pfizer Inc. (US)、Lilly (US)
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：天然、合成
・用途別分析2017年-2028年：糖尿病、心不全、喘息、関節リウマチ、その他
・ガレクチン阻害治療薬の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・ガレクチン阻害治療薬のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・ガレクチン阻害治療薬のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・ガレクチン阻害治療薬の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・ガレクチン阻害治療薬の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Galectin Inhibitor Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Galectin Inhibitor Therapeutics market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Diabetes accounting for % of the Galectin Inhibitor Therapeutics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Natural segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Galectin Inhibitor Therapeutics include GlycoMimetics (US), Galectin Therapeutics Inc (US), G3 Pharmaceuticals (India), iTeos (US), and MandalMed, Inc (US), etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Galectin Inhibitor Therapeutics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Natural
Synthetic
Market segment by Application can be divided into
Diabetes
Heart Failure
Asthma
Rheumatoid Arthritis
Other
The key market players for global Galectin Inhibitor Therapeutics market are listed below:
GlycoMimetics (US)
Galectin Therapeutics Inc (US)
G3 Pharmaceuticals (India)
iTeos (US)
MandalMed, Inc (US)
Angion (US)
Novartis AG (Switzerland)
Galecto Biotech (Denmark)
Pfizer Inc. (US)
Lilly (US)
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Galectin Inhibitor Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Galectin Inhibitor Therapeutics, with price, sales, revenue and global market share of Galectin Inhibitor Therapeutics from 2019 to 2022.
Chapter 3, the Galectin Inhibitor Therapeutics competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Galectin Inhibitor Therapeutics breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Galectin Inhibitor Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Galectin Inhibitor Therapeutics.
Chapter 13, 14, and 15, to describe Galectin Inhibitor Therapeutics sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Galectin Inhibitor Therapeutics Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Galectin Inhibitor Therapeutics Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Natural
1.2.3 Synthetic
1.3 Market Analysis by Application
1.3.1 Overview: Global Galectin Inhibitor Therapeutics Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Diabetes
1.3.3 Heart Failure
1.3.4 Asthma
1.3.5 Rheumatoid Arthritis
1.3.6 Other
1.4 Global Galectin Inhibitor Therapeutics Market Size & Forecast
1.4.1 Global Galectin Inhibitor Therapeutics Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Galectin Inhibitor Therapeutics Sales in Volume (2017-2028)
1.4.3 Global Galectin Inhibitor Therapeutics Price (2017-2028)
1.5 Global Galectin Inhibitor Therapeutics Production Capacity Analysis
1.5.1 Global Galectin Inhibitor Therapeutics Total Production Capacity (2017-2028)
1.5.2 Global Galectin Inhibitor Therapeutics Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Galectin Inhibitor Therapeutics Market Drivers
1.6.2 Galectin Inhibitor Therapeutics Market Restraints
1.6.3 Galectin Inhibitor Therapeutics Trends Analysis
2 Manufacturers Profiles
2.1 GlycoMimetics (US)
2.1.1 GlycoMimetics (US) Details
2.1.2 GlycoMimetics (US) Major Business
2.1.3 GlycoMimetics (US) Galectin Inhibitor Therapeutics Product and Services
2.1.4 GlycoMimetics (US) Galectin Inhibitor Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Galectin Therapeutics Inc (US)
2.2.1 Galectin Therapeutics Inc (US) Details
2.2.2 Galectin Therapeutics Inc (US) Major Business
2.2.3 Galectin Therapeutics Inc (US) Galectin Inhibitor Therapeutics Product and Services
2.2.4 Galectin Therapeutics Inc (US) Galectin Inhibitor Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 G3 Pharmaceuticals (India)
2.3.1 G3 Pharmaceuticals (India) Details
2.3.2 G3 Pharmaceuticals (India) Major Business
2.3.3 G3 Pharmaceuticals (India) Galectin Inhibitor Therapeutics Product and Services
2.3.4 G3 Pharmaceuticals (India) Galectin Inhibitor Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 iTeos (US)
2.4.1 iTeos (US) Details
2.4.2 iTeos (US) Major Business
2.4.3 iTeos (US) Galectin Inhibitor Therapeutics Product and Services
2.4.4 iTeos (US) Galectin Inhibitor Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 MandalMed, Inc (US)
2.5.1 MandalMed, Inc (US) Details
2.5.2 MandalMed, Inc (US) Major Business
2.5.3 MandalMed, Inc (US) Galectin Inhibitor Therapeutics Product and Services
2.5.4 MandalMed, Inc (US) Galectin Inhibitor Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Angion (US)
2.6.1 Angion (US) Details
2.6.2 Angion (US) Major Business
2.6.3 Angion (US) Galectin Inhibitor Therapeutics Product and Services
2.6.4 Angion (US) Galectin Inhibitor Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Novartis AG (Switzerland)
2.7.1 Novartis AG (Switzerland) Details
2.7.2 Novartis AG (Switzerland) Major Business
2.7.3 Novartis AG (Switzerland) Galectin Inhibitor Therapeutics Product and Services
2.7.4 Novartis AG (Switzerland) Galectin Inhibitor Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Galecto Biotech (Denmark)
2.8.1 Galecto Biotech (Denmark) Details
2.8.2 Galecto Biotech (Denmark) Major Business
2.8.3 Galecto Biotech (Denmark) Galectin Inhibitor Therapeutics Product and Services
2.8.4 Galecto Biotech (Denmark) Galectin Inhibitor Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Pfizer Inc. (US)
2.9.1 Pfizer Inc. (US) Details
2.9.2 Pfizer Inc. (US) Major Business
2.9.3 Pfizer Inc. (US) Galectin Inhibitor Therapeutics Product and Services
2.9.4 Pfizer Inc. (US) Galectin Inhibitor Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Lilly (US)
2.10.1 Lilly (US) Details
2.10.2 Lilly (US) Major Business
2.10.3 Lilly (US) Galectin Inhibitor Therapeutics Product and Services
2.10.4 Lilly (US) Galectin Inhibitor Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Galectin Inhibitor Therapeutics Breakdown Data by Manufacturer
3.1 Global Galectin Inhibitor Therapeutics Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Galectin Inhibitor Therapeutics Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Galectin Inhibitor Therapeutics
3.4 Market Concentration Rate
3.4.1 Top 3 Galectin Inhibitor Therapeutics Manufacturer Market Share in 2021
3.4.2 Top 6 Galectin Inhibitor Therapeutics Manufacturer Market Share in 2021
3.5 Global Galectin Inhibitor Therapeutics Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Galectin Inhibitor Therapeutics Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Galectin Inhibitor Therapeutics Market Size by Region
4.1.1 Global Galectin Inhibitor Therapeutics Sales in Volume by Region (2017-2028)
4.1.2 Global Galectin Inhibitor Therapeutics Revenue by Region (2017-2028)
4.2 North America Galectin Inhibitor Therapeutics Revenue (2017-2028)
4.3 Europe Galectin Inhibitor Therapeutics Revenue (2017-2028)
4.4 Asia-Pacific Galectin Inhibitor Therapeutics Revenue (2017-2028)
4.5 South America Galectin Inhibitor Therapeutics Revenue (2017-2028)
4.6 Middle East and Africa Galectin Inhibitor Therapeutics Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Galectin Inhibitor Therapeutics Sales in Volume by Type (2017-2028)
5.2 Global Galectin Inhibitor Therapeutics Revenue by Type (2017-2028)
5.3 Global Galectin Inhibitor Therapeutics Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Galectin Inhibitor Therapeutics Sales in Volume by Application (2017-2028)
6.2 Global Galectin Inhibitor Therapeutics Revenue by Application (2017-2028)
6.3 Global Galectin Inhibitor Therapeutics Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Galectin Inhibitor Therapeutics Sales by Type (2017-2028)
7.2 North America Galectin Inhibitor Therapeutics Sales by Application (2017-2028)
7.3 North America Galectin Inhibitor Therapeutics Market Size by Country
7.3.1 North America Galectin Inhibitor Therapeutics Sales in Volume by Country (2017-2028)
7.3.2 North America Galectin Inhibitor Therapeutics Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Galectin Inhibitor Therapeutics Sales by Type (2017-2028)
8.2 Europe Galectin Inhibitor Therapeutics Sales by Application (2017-2028)
8.3 Europe Galectin Inhibitor Therapeutics Market Size by Country
8.3.1 Europe Galectin Inhibitor Therapeutics Sales in Volume by Country (2017-2028)
8.3.2 Europe Galectin Inhibitor Therapeutics Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Galectin Inhibitor Therapeutics Sales by Type (2017-2028)
9.2 Asia-Pacific Galectin Inhibitor Therapeutics Sales by Application (2017-2028)
9.3 Asia-Pacific Galectin Inhibitor Therapeutics Market Size by Region
9.3.1 Asia-Pacific Galectin Inhibitor Therapeutics Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Galectin Inhibitor Therapeutics Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Galectin Inhibitor Therapeutics Sales by Type (2017-2028)
10.2 South America Galectin Inhibitor Therapeutics Sales by Application (2017-2028)
10.3 South America Galectin Inhibitor Therapeutics Market Size by Country
10.3.1 South America Galectin Inhibitor Therapeutics Sales in Volume by Country (2017-2028)
10.3.2 South America Galectin Inhibitor Therapeutics Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Galectin Inhibitor Therapeutics Sales by Type (2017-2028)
11.2 Middle East & Africa Galectin Inhibitor Therapeutics Sales by Application (2017-2028)
11.3 Middle East & Africa Galectin Inhibitor Therapeutics Market Size by Country
11.3.1 Middle East & Africa Galectin Inhibitor Therapeutics Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Galectin Inhibitor Therapeutics Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Galectin Inhibitor Therapeutics and Key Manufacturers
12.2 Manufacturing Costs Percentage of Galectin Inhibitor Therapeutics
12.3 Galectin Inhibitor Therapeutics Production Process
12.4 Galectin Inhibitor Therapeutics Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Galectin Inhibitor Therapeutics Typical Distributors
13.3 Galectin Inhibitor Therapeutics Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Galectin Inhibitor Therapeutics Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Galectin Inhibitor Therapeutics Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. GlycoMimetics (US) Basic Information, Manufacturing Base and Competitors
Table 4. GlycoMimetics (US) Major Business
Table 5. GlycoMimetics (US) Galectin Inhibitor Therapeutics Product and Services
Table 6. GlycoMimetics (US) Galectin Inhibitor Therapeutics Sales (Kiloton), Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Galectin Therapeutics Inc (US) Basic Information, Manufacturing Base and Competitors
Table 8. Galectin Therapeutics Inc (US) Major Business
Table 9. Galectin Therapeutics Inc (US) Galectin Inhibitor Therapeutics Product and Services
Table 10. Galectin Therapeutics Inc (US) Galectin Inhibitor Therapeutics Sales (Kiloton), Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. G3 Pharmaceuticals (India) Basic Information, Manufacturing Base and Competitors
Table 12. G3 Pharmaceuticals (India) Major Business
Table 13. G3 Pharmaceuticals (India) Galectin Inhibitor Therapeutics Product and Services
Table 14. G3 Pharmaceuticals (India) Galectin Inhibitor Therapeutics Sales (Kiloton), Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. iTeos (US) Basic Information, Manufacturing Base and Competitors
Table 16. iTeos (US) Major Business
Table 17. iTeos (US) Galectin Inhibitor Therapeutics Product and Services
Table 18. iTeos (US) Galectin Inhibitor Therapeutics Sales (Kiloton), Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. MandalMed, Inc (US) Basic Information, Manufacturing Base and Competitors
Table 20. MandalMed, Inc (US) Major Business
Table 21. MandalMed, Inc (US) Galectin Inhibitor Therapeutics Product and Services
Table 22. MandalMed, Inc (US) Galectin Inhibitor Therapeutics Sales (Kiloton), Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Angion (US) Basic Information, Manufacturing Base and Competitors
Table 24. Angion (US) Major Business
Table 25. Angion (US) Galectin Inhibitor Therapeutics Product and Services
Table 26. Angion (US) Galectin Inhibitor Therapeutics Sales (Kiloton), Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Novartis AG (Switzerland) Basic Information, Manufacturing Base and Competitors
Table 28. Novartis AG (Switzerland) Major Business
Table 29. Novartis AG (Switzerland) Galectin Inhibitor Therapeutics Product and Services
Table 30. Novartis AG (Switzerland) Galectin Inhibitor Therapeutics Sales (Kiloton), Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Galecto Biotech (Denmark) Basic Information, Manufacturing Base and Competitors
Table 32. Galecto Biotech (Denmark) Major Business
Table 33. Galecto Biotech (Denmark) Galectin Inhibitor Therapeutics Product and Services
Table 34. Galecto Biotech (Denmark) Galectin Inhibitor Therapeutics Sales (Kiloton), Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Pfizer Inc. (US) Basic Information, Manufacturing Base and Competitors
Table 36. Pfizer Inc. (US) Major Business
Table 37. Pfizer Inc. (US) Galectin Inhibitor Therapeutics Product and Services
Table 38. Pfizer Inc. (US) Galectin Inhibitor Therapeutics Sales (Kiloton), Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Lilly (US) Basic Information, Manufacturing Base and Competitors
Table 40. Lilly (US) Major Business
Table 41. Lilly (US) Galectin Inhibitor Therapeutics Product and Services
Table 42. Lilly (US) Galectin Inhibitor Therapeutics Sales (Kiloton), Price (US$/Ton), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Global Galectin Inhibitor Therapeutics Sales by Manufacturer (2019, 2020, 2021, and 2022) & (Kiloton)
Table 44. Global Galectin Inhibitor Therapeutics Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 45. Market Position of Manufacturers in Galectin Inhibitor Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 46. Global Galectin Inhibitor Therapeutics Production Capacity by Company, (Kiloton): 2020 VS 2021
Table 47. Head Office and Galectin Inhibitor Therapeutics Production Site of Key Manufacturer
Table 48. Galectin Inhibitor Therapeutics New Entrant and Capacity Expansion Plans
Table 49. Galectin Inhibitor Therapeutics Mergers & Acquisitions in the Past Five Years
Table 50. Global Galectin Inhibitor Therapeutics Sales by Region (2017-2022) & (Kiloton)
Table 51. Global Galectin Inhibitor Therapeutics Sales by Region (2023-2028) & (Kiloton)
Table 52. Global Galectin Inhibitor Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 53. Global Galectin Inhibitor Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 54. Global Galectin Inhibitor Therapeutics Sales by Type (2017-2022) & (Kiloton)
Table 55. Global Galectin Inhibitor Therapeutics Sales by Type (2023-2028) & (Kiloton)
Table 56. Global Galectin Inhibitor Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 57. Global Galectin Inhibitor Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 58. Global Galectin Inhibitor Therapeutics Price by Type (2017-2022) & (US$/Ton)
Table 59. Global Galectin Inhibitor Therapeutics Price by Type (2023-2028) & (US$/Ton)
Table 60. Global Galectin Inhibitor Therapeutics Sales by Application (2017-2022) & (Kiloton)
Table 61. Global Galectin Inhibitor Therapeutics Sales by Application (2023-2028) & (Kiloton)
Table 62. Global Galectin Inhibitor Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 63. Global Galectin Inhibitor Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 64. Global Galectin Inhibitor Therapeutics Price by Application (2017-2022) & (US$/Ton)
Table 65. Global Galectin Inhibitor Therapeutics Price by Application (2023-2028) & (US$/Ton)
Table 66. North America Galectin Inhibitor Therapeutics Sales by Country (2017-2022) & (Kiloton)
Table 67. North America Galectin Inhibitor Therapeutics Sales by Country (2023-2028) & (Kiloton)
Table 68. North America Galectin Inhibitor Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 69. North America Galectin Inhibitor Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 70. North America Galectin Inhibitor Therapeutics Sales by Type (2017-2022) & (Kiloton)
Table 71. North America Galectin Inhibitor Therapeutics Sales by Type (2023-2028) & (Kiloton)
Table 72. North America Galectin Inhibitor Therapeutics Sales by Application (2017-2022) & (Kiloton)
Table 73. North America Galectin Inhibitor Therapeutics Sales by Application (2023-2028) & (Kiloton)
Table 74. Europe Galectin Inhibitor Therapeutics Sales by Country (2017-2022) & (Kiloton)
Table 75. Europe Galectin Inhibitor Therapeutics Sales by Country (2023-2028) & (Kiloton)
Table 76. Europe Galectin Inhibitor Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 77. Europe Galectin Inhibitor Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 78. Europe Galectin Inhibitor Therapeutics Sales by Type (2017-2022) & (Kiloton)
Table 79. Europe Galectin Inhibitor Therapeutics Sales by Type (2023-2028) & (Kiloton)
Table 80. Europe Galectin Inhibitor Therapeutics Sales by Application (2017-2022) & (Kiloton)
Table 81. Europe Galectin Inhibitor Therapeutics Sales by Application (2023-2028) & (Kiloton)
Table 82. Asia-Pacific Galectin Inhibitor Therapeutics Sales by Region (2017-2022) & (Kiloton)
Table 83. Asia-Pacific Galectin Inhibitor Therapeutics Sales by Region (2023-2028) & (Kiloton)
Table 84. Asia-Pacific Galectin Inhibitor Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 85. Asia-Pacific Galectin Inhibitor Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 86. Asia-Pacific Galectin Inhibitor Therapeutics Sales by Type (2017-2022) & (Kiloton)
Table 87. Asia-Pacific Galectin Inhibitor Therapeutics Sales by Type (2023-2028) & (Kiloton)
Table 88. Asia-Pacific Galectin Inhibitor Therapeutics Sales by Application (2017-2022) & (Kiloton)
Table 89. Asia-Pacific Galectin Inhibitor Therapeutics Sales by Application (2023-2028) & (Kiloton)
Table 90. South America Galectin Inhibitor Therapeutics Sales by Country (2017-2022) & (Kiloton)
Table 91. South America Galectin Inhibitor Therapeutics Sales by Country (2023-2028) & (Kiloton)
Table 92. South America Galectin Inhibitor Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 93. South America Galectin Inhibitor Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 94. South America Galectin Inhibitor Therapeutics Sales by Type (2017-2022) & (Kiloton)
Table 95. South America Galectin Inhibitor Therapeutics Sales by Type (2023-2028) & (Kiloton)
Table 96. South America Galectin Inhibitor Therapeutics Sales by Application (2017-2022) & (Kiloton)
Table 97. South America Galectin Inhibitor Therapeutics Sales by Application (2023-2028) & (Kiloton)
Table 98. Middle East & Africa Galectin Inhibitor Therapeutics Sales by Region (2017-2022) & (Kiloton)
Table 99. Middle East & Africa Galectin Inhibitor Therapeutics Sales by Region (2023-2028) & (Kiloton)
Table 100. Middle East & Africa Galectin Inhibitor Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 101. Middle East & Africa Galectin Inhibitor Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 102. Middle East & Africa Galectin Inhibitor Therapeutics Sales by Type (2017-2022) & (Kiloton)
Table 103. Middle East & Africa Galectin Inhibitor Therapeutics Sales by Type (2023-2028) & (Kiloton)
Table 104. Middle East & Africa Galectin Inhibitor Therapeutics Sales by Application (2017-2022) & (Kiloton)
Table 105. Middle East & Africa Galectin Inhibitor Therapeutics Sales by Application (2023-2028) & (Kiloton)
Table 106. Galectin Inhibitor Therapeutics Raw Material
Table 107. Key Manufacturers of Galectin Inhibitor Therapeutics Raw Materials
Table 108. Direct Channel Pros & Cons
Table 109. Indirect Channel Pros & Cons
Table 110. Galectin Inhibitor Therapeutics Typical Distributors
Table 111. Galectin Inhibitor Therapeutics Typical Customers
List of Figures
Figure 1. Galectin Inhibitor Therapeutics Picture
Figure 2. Global Galectin Inhibitor Therapeutics Revenue Market Share by Type in 2021
Figure 3. Natural
Figure 4. Synthetic
Figure 5. Global Galectin Inhibitor Therapeutics Revenue Market Share by Application in 2021
Figure 6. Diabetes
Figure 7. Heart Failure
Figure 8. Asthma
Figure 9. Rheumatoid Arthritis
Figure 10. Other
Figure 11. Global Galectin Inhibitor Therapeutics Revenue, (USD Million) & (Kiloton): 2017 & 2021 & 2028
Figure 12. Global Galectin Inhibitor Therapeutics Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Galectin Inhibitor Therapeutics Sales (2017-2028) & (Kiloton)
Figure 14. Global Galectin Inhibitor Therapeutics Price (2017-2028) & (US$/Ton)
Figure 15. Global Galectin Inhibitor Therapeutics Production Capacity (2017-2028) & (Kiloton)
Figure 16. Global Galectin Inhibitor Therapeutics Production Capacity by Geographic Region: 2022 VS 2028
Figure 17. Galectin Inhibitor Therapeutics Market Drivers
Figure 18. Galectin Inhibitor Therapeutics Market Restraints
Figure 19. Galectin Inhibitor Therapeutics Market Trends
Figure 20. Global Galectin Inhibitor Therapeutics Sales Market Share by Manufacturer in 2021
Figure 21. Global Galectin Inhibitor Therapeutics Revenue Market Share by Manufacturer in 2021
Figure 22. Galectin Inhibitor Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 23. Top 3 Galectin Inhibitor Therapeutics Manufacturer (Revenue) Market Share in 2021
Figure 24. Top 6 Galectin Inhibitor Therapeutics Manufacturer (Revenue) Market Share in 2021
Figure 25. Global Galectin Inhibitor Therapeutics Sales Market Share by Region (2017-2028)
Figure 26. Global Galectin Inhibitor Therapeutics Revenue Market Share by Region (2017-2028)
Figure 27. North America Galectin Inhibitor Therapeutics Revenue (2017-2028) & (USD Million)
Figure 28. Europe Galectin Inhibitor Therapeutics Revenue (2017-2028) & (USD Million)
Figure 29. Asia-Pacific Galectin Inhibitor Therapeutics Revenue (2017-2028) & (USD Million)
Figure 30. South America Galectin Inhibitor Therapeutics Revenue (2017-2028) & (USD Million)
Figure 31. Middle East & Africa Galectin Inhibitor Therapeutics Revenue (2017-2028) & (USD Million)
Figure 32. Global Galectin Inhibitor Therapeutics Sales Market Share by Type (2017-2028)
Figure 33. Global Galectin Inhibitor Therapeutics Revenue Market Share by Type (2017-2028)
Figure 34. Global Galectin Inhibitor Therapeutics Price by Type (2017-2028) & (US$/Ton)
Figure 35. Global Galectin Inhibitor Therapeutics Sales Market Share by Application (2017-2028)
Figure 36. Global Galectin Inhibitor Therapeutics Revenue Market Share by Application (2017-2028)
Figure 37. Global Galectin Inhibitor Therapeutics Price by Application (2017-2028) & (US$/Ton)
Figure 38. North America Galectin Inhibitor Therapeutics Sales Market Share by Type (2017-2028)
Figure 39. North America Galectin Inhibitor Therapeutics Sales Market Share by Application (2017-2028)
Figure 40. North America Galectin Inhibitor Therapeutics Sales Market Share by Country (2017-2028)
Figure 41. North America Galectin Inhibitor Therapeutics Revenue Market Share by Country (2017-2028)
Figure 42. United States Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Canada Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Mexico Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Europe Galectin Inhibitor Therapeutics Sales Market Share by Type (2017-2028)
Figure 46. Europe Galectin Inhibitor Therapeutics Sales Market Share by Application (2017-2028)
Figure 47. Europe Galectin Inhibitor Therapeutics Sales Market Share by Country (2017-2028)
Figure 48. Europe Galectin Inhibitor Therapeutics Revenue Market Share by Country (2017-2028)
Figure 49. Germany Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. France Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. United Kingdom Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Russia Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Italy Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Asia-Pacific Galectin Inhibitor Therapeutics Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Galectin Inhibitor Therapeutics Sales Market Share by Application (2017-2028)
Figure 56. Asia-Pacific Galectin Inhibitor Therapeutics Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific Galectin Inhibitor Therapeutics Revenue Market Share by Region (2017-2028)
Figure 58. China Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Japan Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Korea Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. India Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Southeast Asia Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Australia Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. South America Galectin Inhibitor Therapeutics Sales Market Share by Type (2017-2028)
Figure 65. South America Galectin Inhibitor Therapeutics Sales Market Share by Application (2017-2028)
Figure 66. South America Galectin Inhibitor Therapeutics Sales Market Share by Country (2017-2028)
Figure 67. South America Galectin Inhibitor Therapeutics Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East & Africa Galectin Inhibitor Therapeutics Sales Market Share by Type (2017-2028)
Figure 71. Middle East & Africa Galectin Inhibitor Therapeutics Sales Market Share by Application (2017-2028)
Figure 72. Middle East & Africa Galectin Inhibitor Therapeutics Sales Market Share by Region (2017-2028)
Figure 73. Middle East & Africa Galectin Inhibitor Therapeutics Revenue Market Share by Region (2017-2028)
Figure 74. Turkey Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Egypt Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Saudi Arabia Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. South Africa Galectin Inhibitor Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Manufacturing Cost Structure Analysis of Galectin Inhibitor Therapeutics in 2021
Figure 79. Manufacturing Process Analysis of Galectin Inhibitor Therapeutics
Figure 80. Galectin Inhibitor Therapeutics Industrial Chain
Figure 81. Sales Channel: Direct Channel vs Indirect Channel
Figure 82. Methodology
Figure 83. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界のRNAポリメラーゼ阻害剤市場2022年：市場規模予測（～2028年）
  • エピジェネティック治療のグローバル市場展望 2023年-2029年：PRAP（ホスホリボシルピロリン酸アミドトランスフェラーゼ）阻害剤、キナーゼ阻害剤、IDH（イソクエン酸脱水素酵素）阻害剤、HDAC（ヒストン脱アセチル化酵素）阻害剤、DNMT（DNAメチルトランスフェラーゼ）阻害剤
  • 世界のCDK4及び6阻害医薬品市場2022年：市場規模予測（～2028年）
  • 世界のプラスミノーゲンアクチベーターインヒビター1市場2022年：市場規模予測（～2028年）
  • 世界のアルファ-1 プロテイナーゼ阻害剤市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19342 )"世界のガレクチン阻害治療薬市場2022年：市場規模予測（～2028年）" (英文：Global Galectin Inhibitor Therapeutics Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。